Business Wire

Translated Unleashes Full GPT-4 Potential for Businesses Operating in Languages Other Than English

5.6.2023 18:06:00 EEST | Business Wire | Press release

Share

In a significant breakthrough for generative AI and content creation, Translated, a leader in AI-enabled language solutions, is proud to introduce its innovative language model T-LM (Translated Language Model). T-LM will help unlock the full potential of OpenAI’s GPT-4 for businesses around the world. It provides companies with a cost-effective solution to create and restructure content in 200 languages, bridging the performance gap between GPT-4 in English and non-English languages.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005702/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Until now, GPT's impressive performance has been a privilege of the English-speaking world. Companies operating in languages other than English have often found their performance lagging behind that of GPT models from several years ago, with some languages trailing by as much as three years. For these companies, the performance gap in understanding, generating, and restructuring content was an ongoing challenge that often prevented them from taking full advantage of generative AI. Additionally, using GPT-4 in non-English languages can cost up to 15 times more (see attached charts). Translated's T-LM service integrates the company’s award-winning adaptive machine translation (MT) with OpenAI's GPT-4 to bring advanced generative AI capabilities to every business in the languages spoken by 95% of the world's population.

Marco Trombetti, CEO of Translated, expressed his excitement about the project: "The predominance of English in generative AI is creating an unfair competitive advantage. With T-LM, we're democratizing access to this innovative technology, enhancing efficiencies and preserving competitiveness for businesses operating in languages other than English worldwide."

The disparity in GPT-4’s performance between English and other languages arises from the predominance of English-centric sources – such as the Common Crawl dataset and Wikipedia – in training data, leading to inferior outcomes in non-English languages. T-LM addresses this disparity by translating the initial prompt from the source language to English and then back to the user's language using a specialized model. This approach also lowers the cost of using GPT-4 in languages other than English, since the pricing model is based on text segmentation (tokenization) that is optimized for English.

Use cases for T-LM include assisting global content creation teams in content creation, enhancing multilingual customer support, and facilitating the creation of user-generated content for global platforms.

T-LM is available now through API. More information on the service can be found at translatedlabs.com/gpt.

With T-LM, Translated is underlining its commitment to allow everyone to understand and be understood in their own language and to further collaboration with OpenAI in its pursuit of this mission.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contact
Silvio Gulizia
Head of Content
Mail: silvio@translated.com
Mob: +39 393.1044785

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye